{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T20:59:27Z","timestamp":1780779567002,"version":"3.54.1"},"reference-count":202,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["W81XWH2110485"],"award-info":[{"award-number":["W81XWH2110485"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NS120930"],"award-info":[{"award-number":["NS120930"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.neurot.2025.e00826","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T04:39:19Z","timestamp":1766810359000},"page":"e00826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The therapeutic pipeline in migraine: What does the future hold?"],"prefix":"10.1016","volume":"23","author":[{"given":"Mohammed","family":"Gamal-Eltrabily","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Belen","family":"Salinas-Abarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Romero-Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Akerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.neurot.2025.e00826_bib1","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJM199108013250504","article-title":"Treatment of migraine attacks with sumatriptan","volume":"325","year":"1991","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00826_bib2","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2165\/00003495-200060060-00003","article-title":"Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy","volume":"60","author":"Tfelt-Hansen","year":"2000","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00826_bib3","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa030505","article-title":"Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine","volume":"350","author":"Olesen","year":"2004","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00826_bib4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ana.410230214","article-title":"Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system","volume":"23","author":"Goadsby","year":"1988","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00826_bib5","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/WCO.0000000000000548","article-title":"Calcitonin-gene-related peptide pathway mAbs and migraine prevention","volume":"31","author":"Paemeleire","year":"2018","journal-title":"Curr Opin Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00826_bib6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/ana.23996","article-title":"Therapeutic prospects for migraine: can paradise be regained?","volume":"74","author":"Goadsby","year":"2013","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00826_bib7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s10194-020-01212-4","article-title":"Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials","volume":"22","author":"Silberstein","year":"2021","journal-title":"J Headache Pain"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00826_bib8","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s11916-022-01077-z","article-title":"Real-world patient experience of CGRP-targeting therapy for migraine: a narrative review","volume":"26","author":"Murray","year":"2022","journal-title":"Curr Pain Headache Rep"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00826_bib9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s10194-022-01408-w","article-title":"Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study","volume":"23","author":"Ornello","year":"2022","journal-title":"J Headache Pain"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00826_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10194-020-01213-3","article-title":"Association between response to triptans and response to erenumab: real-life data","volume":"22","author":"Frattale","year":"2021","journal-title":"J Headache Pain"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00826_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/ph16070934","article-title":"A scoping review and meta-analysis of Anti-CGRP monoclonal antibodies: predicting response","volume":"16","author":"Hong","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.neurot.2025.e00826_bib12","first-page":"357","article-title":"Efficacy and tolerability of the neurogenic inflammation inhibitor, 4991W93 in the acute treatment of migraine","volume":"19","author":"Earl","year":"1999","journal-title":"Cephalalgia"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00826_bib13","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/1531-8249(200002)47:2<238::AID-ANA15>3.0.CO;2-L","article-title":"No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: results of two randomized, double-blind, placebo-controlled clinical trials","volume":"47","author":"Roon","year":"2000","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00826_bib14","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1046\/j.1468-2982.2001.00161.x","article-title":"Lanepitant, an NK-1 antagonist, in migraine prevention","volume":"21","author":"Goldstein","year":"2001","journal-title":"Cephalalgia"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00826_bib15","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1177\/0333102410370875","article-title":"Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache","volume":"30","author":"Hoivik","year":"2010","journal-title":"Cephalalgia"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00826_bib16","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/acn3.302","article-title":"Metabotropic glutamate receptor 5: a target for migraine therapy","volume":"3","author":"Waung","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"issue":"19","key":"10.1016\/j.neurot.2025.e00826_bib17","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJMra1915327","article-title":"Migraine","volume":"383","author":"Ashina","year":"2020","journal-title":"N Engl J Med"},{"issue":"10283","key":"10.1016\/j.neurot.2025.e00826_bib18","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)32162-0","article-title":"Migraine: disease characterisation, biomarkers, and precision medicine","volume":"397","author":"Ashina","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00826_bib19","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nrneurol.2017.137","article-title":"Human models of migraine - short-term pain for long-term gain","volume":"13","author":"Ashina","year":"2017","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00826_bib20","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1093\/brain\/awab136","article-title":"Opening of ATP sensitive potassium channels causes migraine attacks with aura","volume":"144","author":"Al-Karagholi","year":"2021","journal-title":"Brain"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00826_bib21","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1097\/j.pain.0000000000002238","article-title":"Opening of BKCa channels causes migraine attacks: a new downstream target for the treatment of migraine","volume":"162","author":"Al-Karagholi","year":"2021","journal-title":"Pain"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00826_bib22","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1093\/brain\/awz199","article-title":"Opening of ATP-sensitive potassium channels causes migraine attacks: a new target for the treatment of migraine","volume":"142","author":"Al-Karagholi","year":"2019","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00826_bib23","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s10194-017-0800-8","article-title":"The K(ATP) channel in migraine pathophysiology: a novel therapeutic target for migraine","volume":"18","author":"Al-Karagholi","year":"2017","journal-title":"J Headache Pain"},{"issue":"15","key":"10.1016\/j.neurot.2025.e00826_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/cells11152406","article-title":"ATP-sensitive potassium channels in migraine: translational findings and therapeutic potential","volume":"11","author":"Clement","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00826_bib25","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1152\/physrev.00021.2009","article-title":"Inwardly rectifying potassium channels: their structure, function, and physiological roles","volume":"90","author":"Hibino","year":"2010","journal-title":"Physiol Rev"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00826_bib26","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1161\/HYPERTENSIONAHA.114.03116","article-title":"The ATP-sensitive potassium channel subunit, Kir6.1, in vascular smooth muscle plays a major role in blood pressure control","volume":"64","author":"Aziz","year":"2014","journal-title":"Hypertension"},{"issue":"4914","key":"10.1016\/j.neurot.2025.e00826_bib27","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.2501869","article-title":"Hyperpolarizing vasodilators activate ATP-sensitive K+ channels in arterial smooth muscle","volume":"245","author":"Standen","year":"1989","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00826_bib28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/0333102411430266","article-title":"K(ATP) channel openers in the trigeminovascular system","volume":"32","author":"Ploug","year":"2012","journal-title":"Cephalalgia"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00826_bib29","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0079-6107(02)00053-6","article-title":"Physiological and pathophysiological roles of ATP-sensitive K+ channels","volume":"81","author":"Seino","year":"2003","journal-title":"Prog Biophys Mol Biol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00826_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/ph16030438","article-title":"Involvement of potassium channel signalling in migraine pathophysiology","volume":"16","author":"Al-Karagholi","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00826_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/ph16020225","article-title":"Pharmacological profiling of K(ATP) channel modulators: an outlook for new treatment opportunities for migraine","volume":"16","author":"Dyhring","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00826_bib32","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1468-2982.2004.00848.x","article-title":"Role of KATP channels in the regulation of rat dura and pia artery diameter","volume":"25","author":"Gozalov","year":"2005","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00826_bib33","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s10194-023-01627-9","article-title":"Levcromakalim provokes an acute rapid-onset migraine-like phenotype without inducing cortical spreading depolarization","volume":"24","author":"Alpay","year":"2023","journal-title":"J Headache Pain"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00826_bib34","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/03331024211053570","article-title":"Smooth muscle ATP-sensitive potassium channels mediate migraine-relevant hypersensitivity in mouse models","volume":"42","author":"Christensen","year":"2022","journal-title":"Cephalalgia"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00826_bib35","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.pain.2013.10.004","article-title":"Characterization of a novel model of chronic migraine","volume":"155","author":"Pradhan","year":"2014","journal-title":"Pain"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00826_bib36","doi-asserted-by":"crossref","DOI":"10.1177\/03331024251359237","article-title":"Opening of ATP-sensitive potassium channels activates meningeal nociceptors: implications for the origin of migraine headache","volume":"45","author":"Christensen","year":"2025","journal-title":"Cephalalgia"},{"issue":"14","key":"10.1016\/j.neurot.2025.e00826_bib37","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1177\/03331024211038884","article-title":"CGRP-dependent signalling pathways involved in mouse models of GTN- cilostazol- and levcromakalim-induced migraine","volume":"41","author":"Christensen","year":"2021","journal-title":"Cephalalgia"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00826_bib38","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/head.13634","article-title":"Levcromakalim, an adenosine triphosphate-sensitive potassium channel opener, dilates extracerebral but not cerebral arteries","volume":"59","author":"Al-Karagholi","year":"2019","journal-title":"Headache"},{"key":"10.1016\/j.neurot.2025.e00826_bib39","series-title":"Structural and functional cerebral changes after infusion of ATP sensitive potassium channel opener levcromakalim [Internet]","year":"2022"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00826_bib40","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1177\/0333102420925513","article-title":"ATP sensitive potassium (K(ATP)) channel inhibition: a promising new drug target for migraine","volume":"40","author":"Christensen","year":"2020","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00826_bib41","first-page":"11","article-title":"Pituitary adenylate-cyclase-activating peptides relax human coronary arteries by activating K(ATP) and K(Ca) channels in smooth muscle cells","volume":"34","author":"Bruch","year":"1997","journal-title":"J Vasc Res"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00826_bib42","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/j.1526-4610.2008.01205.x","article-title":"Role of K ATP channels in cephalic vasodilatation induced by calcitonin gene-related peptide, nitric oxide, and transcranial electrical stimulation in the rat","volume":"48","author":"Gozalov","year":"2008","journal-title":"Headache"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00826_bib43","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/bjp.2008.86","article-title":"K(ATP) channel expression and pharmacological in vivo and in vitro studies of the K(ATP) channel blocker PNU-37883A in rat middle meningeal arteries","volume":"154","author":"Ploug","year":"2008","journal-title":"Br J Pharmacol"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00826_bib44","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1177\/0333102420949863","article-title":"Effect of K(ATP) channel blocker glibenclamide on levcromakalim-induced headache","volume":"40","author":"Al-Karagholi","year":"2020","journal-title":"Cephalalgia"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00826_bib45","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1177\/0271678X20959294","article-title":"Cerebrovascular effects of glibenclamide investigated using high-resolution magnetic resonance imaging in healthy volunteers","volume":"41","author":"Al-Karagholi","year":"2021","journal-title":"J Cerebr Blood Flow Metabol"},{"key":"10.1016\/j.neurot.2025.e00826_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.652136","article-title":"The effect of K (ATP) channel blocker glibenclamide on CGRP-induced headache and hemodynamic in healthy volunteers","volume":"12","author":"Coskun","year":"2021","journal-title":"Front Physiol"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00826_bib47","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1177\/03331024221080574","article-title":"Effect of K(ATP) channel blocker glibenclamide on PACAP38-induced headache and hemodynamic","volume":"42","author":"Kokoti","year":"2022","journal-title":"Cephalalgia"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00826_bib48","first-page":"247","article-title":"Cardiovascular effects of the K-ATP channel blocker U-37883A and structurally related morpholinoguanidines","volume":"18","author":"Humphrey","year":"1996","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"10.1016\/j.neurot.2025.e00826_bib49","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/237865","article-title":"Effects of chronic PPAR-agonist treatment on cardiac structure and function, blood pressure, and kidney in healthy sprague-dawley rats","volume":"2009","author":"Blasi","year":"2009","journal-title":"PPAR Res"},{"issue":"23","key":"10.1016\/j.neurot.2025.e00826_bib50","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1113\/jphysiol.2011.215533","article-title":"Intracellular BK(Ca) (iBK(Ca)) channels","volume":"590","author":"Singh","year":"2012","journal-title":"J Physiol"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00826_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/antiox9080760","article-title":"BK(Ca) channels as targets for cardioprotection","volume":"9","author":"Szteyn","year":"2020","journal-title":"Antioxidants"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00826_bib52","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1085\/jgp.20028605","article-title":"Coupling between voltage sensor activation, Ca2+ binding and channel opening in large conductance (BK) potassium channels","volume":"120","author":"Horrigan","year":"2002","journal-title":"J Gen Physiol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00826_bib53","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00441-008-0701-x","article-title":"Molecular studies of BKCa channels in intracranial arteries: presence and localization","volume":"334","author":"Wulf","year":"2008","journal-title":"Cell Tissue Res"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00826_bib54","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/j.1468-2982.2009.01849.x","article-title":"Large conductance calcium-activated potassium channels (BKCa) modulate trigeminovascular nociceptive transmission","volume":"29","author":"Storer","year":"2009","journal-title":"Cephalalgia"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00826_bib55","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.neuroscience.2010.02.063","article-title":"Localization of large conductance calcium-activated potassium channels and their effect on calcitonin gene-related peptide release in the rat trigemino-neuronal pathway","volume":"167","author":"Wulf-Johansson","year":"2010","journal-title":"Neuroscience"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00826_bib56","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/j.1468-2982.2007.01409.x","article-title":"Role of BK(Ca) channels in cephalic vasodilation induced by CGRP, NO and transcranial electrical stimulation in the rat","volume":"27","author":"Gozalov","year":"2007","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00826_bib57","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.pain.2010.06.028","article-title":"Inhibition of trigeminovascular dural nociceptive afferents by Ca(2+)-activated K(+) (MaxiK\/BK(Ca)) channel opening","volume":"151","author":"Akerman","year":"2010","journal-title":"Pain"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00826_bib58","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1177\/0333102420940681","article-title":"Opening of BK(Ca) channels alters cerebral hemodynamic and causes headache in healthy volunteers","volume":"40","author":"Al-Karagholi","year":"2020","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00826_bib59","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s10194-023-01567-4","article-title":"Future targets for migraine treatment beyond CGRP","volume":"24","author":"Al-Hassany","year":"2023","journal-title":"J Headache Pain"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00826_bib60","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/bcpt.13787","article-title":"The role of high-conductance calcium-activated potassium channel in headache and migraine pathophysiology","volume":"131","author":"Al-Karagholi","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00826_bib61","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/0333102412472071","article-title":"Pearls and pitfalls in experimental in vivo models of migraine: dural trigeminovascular nociception","volume":"33","author":"Akerman","year":"2013","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neurot.2025.e00826_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108297","article-title":"ThermoTRP channels in pain sexual dimorphism: new insights for drug intervention","volume":"240","author":"Cabanero","year":"2022","journal-title":"Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00826_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20112618","article-title":"Recent progress in TRPM8 modulation: an update","volume":"20","author":"Gonzalez-Muniz","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00826_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/ph10020037","article-title":"Development of TRPM8 antagonists to treat chronic pain and migraine","volume":"10","author":"Weyer","year":"2017","journal-title":"Pharmaceuticals"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00826_bib65","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/head.12948","article-title":"TRPM8 and migraine","volume":"56","author":"Dussor","year":"2016","journal-title":"Headache"},{"key":"10.1016\/j.neurot.2025.e00826_bib66","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/978-3-642-54215-2_22","article-title":"Trpm8","volume":"222","author":"Almaraz","year":"2014","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.neurot.2025.e00826_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173312","article-title":"TRPM8 channels: a review of distribution and clinical role","volume":"882","author":"Liu","year":"2020","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00826_bib68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004366","article-title":"Selectivity in genetic association with sub-classified migraine in women","volume":"10","author":"Chasman","year":"2014","journal-title":"PLoS Genet"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00826_bib69","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/ng.856","article-title":"Genome-wide association study reveals three susceptibility loci for common migraine in the general population","volume":"43","author":"Chasman","year":"2011","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00826_bib70","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1177\/0333102414557841","article-title":"Replication study of previous migraine genome-wide association study findings in a Spanish sample of migraine with aura","volume":"35","author":"Sintas","year":"2015","journal-title":"Cephalalgia"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00826_bib71","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/ng.2307","article-title":"Genome-wide association analysis identifies susceptibility loci for migraine without aura","volume":"44","author":"Freilinger","year":"2012","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00826_bib72","doi-asserted-by":"crossref","first-page":"E21","DOI":"10.25011\/cim.v42i1.32389","article-title":"Association between PRDM16, MEF2D, TRPM8, LRP1 gene polymorphisms and migraine susceptibility in the she ethnic population in China","volume":"42","author":"Fu","year":"2019","journal-title":"Clin Invest Med"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00826_bib73","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-56295-0","article-title":"Reduced TRPM8 expression underpins reduced migraine risk and attenuated cold pain sensation in humans","volume":"9","author":"Gavva","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00826_bib74","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/head.13188","article-title":"Quantitative analysis of mouse dural afferent neurons expressing TRPM8, VGLUT3, and NF200","volume":"58","author":"Ren","year":"2018","journal-title":"Headache"},{"key":"10.1016\/j.neurot.2025.e00826_bib75","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12990-015-0043-0","article-title":"Function and postnatal changes of dural afferent fibers expressing TRPM8 channels","volume":"11","author":"Ren","year":"2015","journal-title":"Mol Pain"},{"key":"10.1016\/j.neurot.2025.e00826_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2024.118464","article-title":"Paeonol and glycyrrhizic acid in combination ameliorate the recurrent nitroglycerin-induced migraine-like phenotype in rats by regulating the GABBR2\/TRPM8\/PRKACA\/TRPV1 pathway","volume":"334","author":"Zhang","year":"2024","journal-title":"J Ethnopharmacol"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00826_bib77","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/0333102415584313","article-title":"Meningeal transient receptor potential channel M8 activation causes cutaneous facial and hindpaw allodynia in a preclinical rodent model of headache","volume":"36","author":"Burgos-Vega","year":"2016","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neurot.2025.e00826_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2023.148725","article-title":"Menthol dural application alters meningeal arteries tone and enhances excitability of trigeminocervical neurons in rats","volume":"1825","author":"Sokolov","year":"2024","journal-title":"Brain Res"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00826_bib79","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1177\/0333102417712719","article-title":"Functional interactions between transient receptor potential M8 and transient receptor potential V1 in the trigeminal system: relevance to migraine pathophysiology","volume":"38","author":"Kayama","year":"2018","journal-title":"Cephalalgia"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00826_bib80","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1097\/j.pain.0000000000002635","article-title":"Transient receptor potential melastatin 8 is required for nitroglycerin- and calcitonin gene-related peptide-induced migraine-like pain behaviors in mice","volume":"163","author":"Wei","year":"2022","journal-title":"Pain"},{"issue":"13","key":"10.1016\/j.neurot.2025.e00826_bib81","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1177\/03331024221114773","article-title":"The effects of certain TRP channels and voltage-gated KCNQ\/Kv7 channel opener retigabine on calcitonin gene-related peptide release in the trigeminovascular system","volume":"42","author":"Citak","year":"2022","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00826_bib82","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s10194-025-02082-4","article-title":"Cold receptor TRPM8 as a target for migraine-associated pain and affective comorbidities","volume":"26","author":"Cabanero","year":"2025","journal-title":"J Headache Pain"},{"key":"10.1016\/j.neurot.2025.e00826_bib83","series-title":"Double-blind, placebo-controlled, single-ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AMG 333 in healthy subjects and subjects with migraines","author":"Randomized","year":"2013"},{"key":"10.1016\/j.neurot.2025.e00826_bib84","series-title":"Randomized, double-blind, placebo-controlled study of elismetrep (K-304) in the treatment of migraine: a range of doses will be evaluated","year":"2025"},{"key":"10.1016\/j.neurot.2025.e00826_bib85","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/1471-2164-7-159","article-title":"Tissue-specific expression of TRP channel genes in the mouse and its variation in three different mouse strains","volume":"7","author":"Kunert-Keil","year":"2006","journal-title":"BMC Genom"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00826_bib86","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s12272-012-1016-8","article-title":"Quantitative analysis of TRP channel genes in mouse organs","volume":"35","author":"Jang","year":"2012","journal-title":"Arch Pharm Res (Seoul)"},{"key":"10.1016\/j.neurot.2025.e00826_bib87","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.phrs.2017.07.014","article-title":"Transient receptor potential TRPM3 channels: pharmacology, signaling, and biological functions","volume":"124","author":"Thiel","year":"2017","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.neurot.2025.e00826_bib88","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fmolb.2018.00073","article-title":"TRP channels as potential targets for sex-related differences in migraine pain","volume":"5","author":"Artero-Morales","year":"2018","journal-title":"Front Mol Biosci"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00826_bib89","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s10194-021-01383-8","article-title":"Migraine-relevant sex-dependent activation of mouse meningeal afferents by TRPM3 agonists","volume":"23","author":"Krivoshein","year":"2022","journal-title":"J Headache Pain"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00826_bib90","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s10194-025-01966-9","article-title":"Sex difference in TRPM3 channel functioning in nociceptive and vascular systems: an emerging target for migraine therapy in females?","volume":"26","author":"Krivoshein","year":"2025","journal-title":"J Headache Pain"},{"issue":"24","key":"10.1016\/j.neurot.2025.e00826_bib91","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222413652","article-title":"Partial agonistic actions of sex hormone steroids on TRPM3 function","volume":"22","author":"Persoons","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00826_bib92","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.neuron.2011.02.051","article-title":"TRPM3 is a nociceptor channel involved in the detection of noxious heat","volume":"70","author":"Vriens","year":"2011","journal-title":"Neuron"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00826_bib93","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1111\/bph.14994","article-title":"Functional expression and pharmacological modulation of TRPM3 in human sensory neurons","volume":"177","author":"Vangeel","year":"2020","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00826_bib94","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12576-024-00937-0","article-title":"TRPM3, TRPM4, and TRPM5 as thermo-sensitive channels","volume":"74","author":"Uchida","year":"2024","journal-title":"J Physiol Sci"},{"issue":"20","key":"10.1016\/j.neurot.2025.e00826_bib95","doi-asserted-by":"crossref","first-page":"6365","DOI":"10.1113\/JP286407","article-title":"Activation of TRPA1 and TRPM3 triggers Ca(2+) waves in central terminals of sensory neurons and facilitates synaptic activity in the spinal dorsal horn","volume":"603","author":"Andrianov","year":"2025","journal-title":"J Physiol"},{"key":"10.1016\/j.neurot.2025.e00826_bib96","article-title":"TRPM3 activation causes CGRP release in trigeminal neurons: implications for migraine mechanisms","author":"Reducha","year":"2025","journal-title":"Headache"},{"key":"10.1016\/j.neurot.2025.e00826_bib97","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jchemneu.2019.01.005","article-title":"Transient receptor potential melastatin-3 in the rat sensory ganglia of the trigeminal, glossopharyngeal and vagus nerves","volume":"96","author":"Yajima","year":"2019","journal-title":"J Chem Neuroanat"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00826_bib98","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/joa.13656","article-title":"Differential immunostaining patterns of transient receptor potential (TRP) ion channels in the rat nodose ganglion","volume":"241","author":"Jawaid","year":"2022","journal-title":"J Anat"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00826_bib99","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1007\/s43440-020-00207-x","article-title":"Spinal mechanisms contributing to the development of pain hypersensitivity induced by sphingolipids in the rat","volume":"73","author":"Wei","year":"2021","journal-title":"Pharmacol Rep"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00826_bib100","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1111\/bph.17472","article-title":"Sex differences in the vasoactive effect of transient receptor potential channels: TRPM3 as a new therapeutic target for (neuro)vascular disorders","volume":"182","author":"Rivera-Mancilla","year":"2025","journal-title":"Br J Pharmacol"},{"issue":"7_Supplement_1","key":"10.1016\/j.neurot.2025.e00826_bib101","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1212\/WNL.0000000000211319","article-title":"BHV-2100, a first-in-class TRPM3 antagonist in development for the treatment of Migraine (P7-12.009)","volume":"104","author":"Emerson","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00826_bib102","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3389\/fnins.2015.00335","article-title":"Oxytocin and vasopressin: linking pituitary neuropeptides and their receptors to social neurocircuits","volume":"9","author":"Baribeau","year":"2015","journal-title":"Front Neurosci"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00826_bib103","doi-asserted-by":"crossref","first-page":"6222","DOI":"10.1111\/ejn.16556","article-title":"Hypothalamic cerebrospinal fluid-contacting neurons project to the rostral agranular insular cortex: an immunofluorescence and ultrastructural analysis in the rat","volume":"60","author":"Mart\u00ednez-Lorenzana","year":"2024","journal-title":"Eur J Neurosci"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00826_bib104","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.biopsych.2015.05.003","article-title":"Intranasal oxytocin: myths and delusions","volume":"79","author":"Leng","year":"2016","journal-title":"Biol Psychiatry"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00826_bib105","doi-asserted-by":"crossref","DOI":"10.1111\/jne.12856","article-title":"Somato-dendritic vasopressin and oxytocin secretion in endocrine and autonomic regulation","volume":"32","author":"Brown","year":"2020","journal-title":"J Neuroendocrinol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00826_bib106","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1152\/physrev.00031.2017","article-title":"The oxytocin receptor: from intracellular signaling to behavior","volume":"98","author":"Jurek","year":"2018","journal-title":"Physiol Rev"},{"issue":"29","key":"10.1016\/j.neurot.2025.e00826_bib107","doi-asserted-by":"crossref","first-page":"5669","DOI":"10.1523\/JNEUROSCI.0962-20.2020","article-title":"The rostral agranular Insular cortex, a new site of oxytocin to induce antinociception","volume":"40","author":"Gamal-Eltrabily","year":"2020","journal-title":"J Neurosci"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00826_bib108","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ejp.1134","article-title":"The role of peripheral vasopressin 1A and oxytocin receptors on the subcutaneous vasopressin antinociceptive effects","volume":"22","author":"Manzano-Garc\u00eda","year":"2018","journal-title":"Eur J Pain"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00826_bib109","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1177\/0333102415618615","article-title":"Oxytocin receptor: expression in the trigeminal nociceptive system and potential role in the treatment of headache disorders","volume":"36","author":"Tzabazis","year":"2016","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00826_bib110","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s10194-020-1079-8","article-title":"The distribution of oxytocin and the oxytocin receptor in rat brain: relation to regions active in migraine","volume":"21","author":"Warfvinge","year":"2020","journal-title":"J Headache Pain"},{"key":"10.1016\/j.neurot.2025.e00826_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2019.113079","article-title":"Inhibition of nociceptive dural input to the trigeminocervical complex through oxytocinergic transmission","volume":"323","author":"Garc\u00eda-Boll","year":"2020","journal-title":"Exp Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00826_bib112","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s10194-021-01299-3","article-title":"Repeated oxytocin prevents central sensitization by regulating synaptic plasticity via oxytocin receptor in a chronic migraine mouse model","volume":"22","author":"Wang","year":"2021","journal-title":"J Headache Pain"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00826_bib113","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/j.pain.0000000000000808","article-title":"Oxytocin alleviates orofacial mechanical hypersensitivity associated with infraorbital nerve injury through vasopressin-1A receptors of the rat trigeminal ganglia","volume":"158","author":"Kubo","year":"2017","journal-title":"Pain"},{"issue":"17","key":"10.1016\/j.neurot.2025.e00826_bib114","article-title":"Hypothalamic paraventricular stimulation inhibits nociceptive wide dynamic range trigeminocervical complex cells via oxytocinergic transmission","volume":"44","author":"Cond\u00e9s-Lara","year":"2024","journal-title":"J Neurosci"},{"issue":"20","key":"10.1016\/j.neurot.2025.e00826_bib115","doi-asserted-by":"crossref","first-page":"8827","DOI":"10.1523\/JNEUROSCI.0439-13.2013","article-title":"Paraventricular hypothalamic regulation of trigeminovascular mechanisms involved in headaches","volume":"33","author":"Robert","year":"2013","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00826_bib116","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/head.13213","article-title":"Generalized pain sensitization and endogenous oxytocin in individuals with symptoms of migraine: a cross-sectional study","volume":"58","author":"You","year":"2018","journal-title":"Headache"},{"issue":"Suppl 2","key":"10.1016\/j.neurot.2025.e00826_bib117","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/head.13082","article-title":"Oxytocin and Migraine headache","volume":"57","author":"Tzabazis","year":"2017","journal-title":"Headache"},{"key":"10.1016\/j.neurot.2025.e00826_bib118","series-title":"A phase 2, enriched-enrollment, randomized-withdrawal, double-blinded, placebo-controlled study to assess the efficacy, tolerability, and safety of intranasal oxytocin in subjects with chronic migraine","year":"2013"},{"key":"10.1016\/j.neurot.2025.e00826_bib119","series-title":"Patients with chronic migraine (PREVENTION study)","article-title":"Double-blind, randomized, multicenter, placebo-controlled, three arm parallel study to evaluate the efficacy and safety of TNX-1900 (Intranasal oxytocin)","year":"2022"},{"key":"10.1016\/j.neurot.2025.e00826_bib120","first-page":"1","volume":"38","year":"2018"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00826_bib121","first-page":"124","article-title":"The anatomical record, volume 78, 1940: hypothalamic lesions and adiposity in the rat","volume":"41","author":"Classics","year":"1983","journal-title":"Nutr Rev"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00826_bib122","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41380-020-00864-7","article-title":"Advances in the field of intranasal oxytocin research: lessons learned and future directions for clinical research","volume":"26","author":"Quintana","year":"2021","journal-title":"Mol Psychiatr"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00826_bib123","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/mp.2017.27","article-title":"Oxytocin by intranasal and intravenous routes reaches the cerebrospinal fluid in rhesus macaques: determination using a novel oxytocin assay","volume":"23","author":"Lee","year":"2018","journal-title":"Mol Psychiatr"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00826_bib124","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1038\/s41467-020-15942-1","article-title":"Labeled oxytocin administered via the intranasal route reaches the brain in rhesus macaques","volume":"11","author":"Lee","year":"2020","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00826_bib125","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1021\/acs.molpharmaceut.7b00991","article-title":"Delivery of oxytocin to the brain for the treatment of autism spectrum disorder by nasal application","volume":"15","author":"Tanaka","year":"2018","journal-title":"Mol Pharm"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00826_bib126","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1526-4610.2007.00842.x","article-title":"The hypothalamic orexinergic system: pain and primary headaches","volume":"47","author":"Holland","year":"2007","journal-title":"Headache J Head Face Pain"},{"key":"10.1016\/j.neurot.2025.e00826_bib127","first-page":"322","article-title":"The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity","volume":"95","author":"De Lecea","year":"1998","journal-title":"Neurobiology"},{"key":"10.1016\/j.neurot.2025.e00826_bib128","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","article-title":"Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior","volume":"92","author":"Sakurai","year":"1998","journal-title":"Cell"},{"issue":"Suppl 2","key":"10.1016\/j.neurot.2025.e00826_bib129","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/head.13078","article-title":"Biology of neuropeptides: orexinergic involvement in primary headache disorders","volume":"57","author":"Holland","year":"2017","journal-title":"Headache"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00826_bib130","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.yfrne.2007.08.001","article-title":"Orexin neuronal circuitry: role in the regulation of sleep and wakefulness","volume":"29","author":"Ohno","year":"2008","journal-title":"Front Neuroendocrinol"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00826_bib131","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/14737175.2024.2328728","article-title":"Orexins and primary headaches: an overview of the neurobiology and clinical impact","volume":"24","author":"Stanyer","year":"2024","journal-title":"Expert Rev Neurother"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00826_bib132","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrneurol.2016.93","article-title":"Chronic migraine: risk factors, mechanisms and treatment","volume":"12","author":"May","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurot.2025.e00826_bib133","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.neuroscience.2014.03.043","article-title":"Dual orexin receptor antagonist 12 inhibits expression of proteins in neurons and glia implicated in peripheral and central sensitization","volume":"269","author":"Cady","year":"2014","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00826_bib134","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1124\/jpet.105.090951","article-title":"Orexin 1 receptor activation attenuates neurogenic dural vasodilation in an animal model of trigeminovascular nociception","volume":"315","author":"Holland","year":"2005","journal-title":"J Pharmacol Exp Therapeut"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00826_bib135","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1111\/j.1460-9568.2006.05168.x","article-title":"Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat","volume":"24","author":"Holland","year":"2006","journal-title":"Eur J Neurosci"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00826_bib136","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.pain.2004.02.005","article-title":"Differential modulation of nociceptive dural input to [hypocretin] orexin A and B receptor activation in the posterior hypothalamic area","volume":"109","author":"Bartsch","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.neurot.2025.e00826_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.107981","article-title":"Activation orexin 1 receptors in the ventrolateral periaqueductal gray matter attenuate nitroglycerin-induced migraine attacks and calcitonin gene related peptide up-regulation in trigeminal nucleus caudalis of rats","volume":"178","author":"Kooshki","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neurot.2025.e00826_bib138","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.nbd.2014.10.022","article-title":"Evidence for orexinergic mechanisms in migraine","volume":"74","author":"Hoffmann","year":"2015","journal-title":"Neurobiol Dis"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00826_bib139","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10194-011-0314-8","article-title":"Evidence for an association between migraine and the hypocretin receptor 1 gene","volume":"12","author":"Rainero","year":"2011","journal-title":"J Headache Pain"},{"key":"10.1016\/j.neurot.2025.e00826_bib140","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3389\/fnmol.2018.00191","article-title":"The new \u2217G29A and G1222A of HCRTR1, 5-HTTLPR of SLC6A4 polymorphisms and Hypocretin-1, serotonin concentrations in migraine patients","volume":"11","author":"Kowalska","year":"2018","journal-title":"Front Mol Neurosci"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00826_bib141","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1468-2982.2008.01566.x","article-title":"Involvement of corticotrophin-releasing factor and orexin-A in chronic migraine and medication-overuse headache: findings from cerebrospinal fluid","volume":"28","author":"Sarchielli","year":"2008","journal-title":"Cephalalgia"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00826_bib142","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/0333102414544979","article-title":"Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis","volume":"35","author":"Chabi","year":"2015","journal-title":"Cephalalgia"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00826_bib143","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1093\/brain\/awae179","article-title":"Nociceptors are functionally Male or female: from mouse to monkey to man","volume":"147","author":"Stratton","year":"2024","journal-title":"Brain"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00826_bib144","doi-asserted-by":"crossref","DOI":"10.1177\/03331024241281493","article-title":"A male-specific mechanism of meningeal nociceptor sensitization promoting migraine headache","volume":"44","author":"Kopruszinski","year":"2024","journal-title":"Cephalalgia"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00826_bib145","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1152\/physrev.2000.80.4.1523","article-title":"Prolactin: structure, function, and regulation of secretion","volume":"80","author":"Freeman","year":"2000","journal-title":"Journal of Physiological Reviews"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00826_bib146","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1210\/edrv.19.3.0334","article-title":"Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice","volume":"19","author":"Bole-Feysot","year":"1998","journal-title":"Endocr Rev"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00826_bib147","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41574-019-0194-6","article-title":"Prolactin - a pleiotropic factor in health and disease","volume":"15","author":"Bernard","year":"2019","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00826_bib148","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s11154-024-09915-8","article-title":"Prolactin: structure, receptors, and functions","volume":"25","author":"Chasseloup","year":"2024","journal-title":"Rev Endocr Metab Disord"},{"issue":"529","key":"10.1016\/j.neurot.2025.e00826_bib149","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay7550","article-title":"The prolactin receptor long isoform regulates nociceptor sensitization and opioid-induced hyperalgesia selectively in females","volume":"12","author":"Chen","year":"2020","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00826_bib150","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1080\/07853890410033892","article-title":"Prolactin and the prolactin receptor: new targets of an old hormone","volume":"36","author":"Harris","year":"2004","journal-title":"Ann Med"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00826_bib151","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4161\/chan.28946","article-title":"Prolactin receptor in regulation of neuronal excitability and channels","volume":"8","author":"Patil","year":"2014","journal-title":"Channels"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00826_bib152","doi-asserted-by":"crossref","DOI":"10.1177\/03331024221136286","article-title":"Prolactin in headache and migraine: a systematic review of clinical studies","volume":"43","author":"Al-Karagholi","year":"2023","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00826_bib153","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/head.14248","article-title":"Prolactin signaling modulates stress-induced behavioral responses in a preclinical mouse model of migraine","volume":"62","author":"Mason","year":"2022","journal-title":"Headache"},{"issue":"31","key":"10.1016\/j.neurot.2025.e00826_bib154","doi-asserted-by":"crossref","first-page":"8126","DOI":"10.1523\/JNEUROSCI.0793-06.2006","article-title":"Prolactin modulates TRPV1 in female rat trigeminal sensory neurons","volume":"26","author":"Diogenes","year":"2006","journal-title":"J Neurosci"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00826_bib155","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/0333102410375626","article-title":"TRPV1 receptor blockade is ineffective in different in vivo models of migraine","volume":"31","author":"Summ","year":"2011","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neurot.2025.e00826_bib156","doi-asserted-by":"crossref","first-page":"S202a","DOI":"10.1016\/S1090-3801(09)60705-9","article-title":"A randomised, two-period cross-over study to investigate the efficacy of the Trpv1 antagonist SB-705498 in acute migrain","volume":"13","author":"Chizh","year":"2009","journal-title":"Eur J Pain"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00826_bib157","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/ana.26070","article-title":"Meningeal CGRP-prolactin interaction evokes female-specific migraine behavior","volume":"89","author":"Avona","year":"2021","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00826_bib158","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/j.pain.0000000000003385","article-title":"Meningeal K ATP channels contribute to behavioral responses in preclinical migraine models","volume":"166","author":"Mei","year":"2025","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00826_bib159","doi-asserted-by":"crossref","DOI":"10.1177\/03331024241313378","article-title":"Prolactin-induced sensitization of trigeminal nociceptors promotes migraine co-morbidity in endometriosis","volume":"45","author":"Lee","year":"2025","journal-title":"Cephalalgia"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00826_bib160","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1093\/brain\/awac104","article-title":"Dysregulation of serum prolactin links the hypothalamus with female nociceptors to promote migraine","volume":"145","author":"Watanabe","year":"2022","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00826_bib161","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/03331024211039813","article-title":"A prolactin-dependent sexually dimorphic mechanism of migraine chronification","volume":"42","author":"Ikegami","year":"2022","journal-title":"Cephalalgia"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00826_bib162","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/0002-9378(83)90571-9","article-title":"Hyperprolactinemia and headaches","volume":"145","author":"Kemmann","year":"1983","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00826_bib163","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10194-006-0272-8","article-title":"High prolactin levels as a worsening factor for migraine","volume":"7","author":"Cavestro","year":"2006","journal-title":"J Headache Pain"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00826_bib164","first-page":"68","article-title":"Comparison the serum level of prolactin among patients with chronic and episodic migraine","volume":"3","author":"Saberi","year":"2013","journal-title":"Journal of Neurology Research"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00826_bib165","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10072-019-04035-7","article-title":"Evidence for hyperprolactinemia in migraineurs: a systematic review and meta-analysis","volume":"41","author":"Noori-Zadeh","year":"2020","journal-title":"Neurol Sci"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00826_bib166","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1590\/0004-282x20190143","article-title":"Resolution of headache after reduction of prolactin levels in hyperprolactinemic patients","volume":"78","author":"Oliveira","year":"2020","journal-title":"Arq Neuropsiquiatr"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00826_bib167","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1526-4610.1995.hed3507430.x","article-title":"Resolution of migraine following bromocriptine treatment of a prolactinoma (Pituitary microadenoma)","volume":"35","author":"Hartman","year":"1995","journal-title":"Headache"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00826_bib168","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10194-008-0016-z","article-title":"Relationship between high prolactine levels and migraine attacks in patients with microprolactinoma","volume":"9","author":"Bosco","year":"2008","journal-title":"J Headache Pain"},{"issue":"16","key":"10.1016\/j.neurot.2025.e00826_bib169","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1177\/0333102412462639","article-title":"Headache in patients with pituitary adenoma: clinical and paraclinical findings","volume":"32","author":"Schankin","year":"2012","journal-title":"Cephalalgia"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00826_bib170","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1177\/0333102413515343","article-title":"Prolactinoma-associated headache and dopamine agonist treatment","volume":"34","author":"Kallestrup","year":"2014","journal-title":"Cephalalgia"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00826_bib171","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s11102-015-0696-8","article-title":"Significant improvement of intractable headache after transsphenoidal surgery in patients with pituitary adenomas; preoperative neuroradiological evaluation and intraoperative intrasellar pressure measurement","volume":"19","author":"Hayashi","year":"2016","journal-title":"Pituitary"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00826_bib172","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/00207454.2021.1881091","article-title":"The effect of topiramate versus flunarizine on the non-headache symptoms of migraine","volume":"133","author":"Li","year":"2023","journal-title":"Int J Neurosci"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00826_bib173","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00726-010-0633-0","article-title":"Reactive nitroxidative species and nociceptive processing: determining the roles for nitric oxide, superoxide, and peroxynitrite in pain","volume":"42","author":"Little","year":"2012","journal-title":"Amino Acids"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00826_bib174","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1073\/pnas.87.4.1620","article-title":"Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide","volume":"87","author":"Beckman","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00826_bib175","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s13311-018-0614-7","article-title":"Targeted nitric oxide synthase inhibitors for migraine","volume":"15","author":"Pradhan","year":"2018","journal-title":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00826_bib176","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1046\/j.1468-2982.1994.014003215.x","article-title":"Platelet superoxide dismutase in migraine and tension-type headache","volume":"14","author":"Shimomura","year":"1994","journal-title":"Cephalalgia"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00826_bib177","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1468-2982.2004.00863.x","article-title":"Platelet membrane fluidity and peroxynitrite levels in migraine patients during headache-free periods","volume":"25","author":"Taffi","year":"2005","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00826_bib178","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0006-8993(99)01985-X","article-title":"Effects of sumatriptan on nitric oxide and superoxide balance during glyceryl trinitrate infusion in the rat. Implications for antimigraine mechanisms","volume":"847","author":"Read","year":"1999","journal-title":"Brain Res"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00826_bib179","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1089\/ars.2010.3208","article-title":"Reactive oxygen species in the regulation of synaptic plasticity and memory","volume":"14","author":"Massaad","year":"2011","journal-title":"Antioxidants Redox Signal"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00826_bib180","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.freeradbiomed.2011.01.026","article-title":"Roles of reactive oxygen and nitrogen species in pain","volume":"51","author":"Salvemini","year":"2011","journal-title":"Free Radic Biol Med"},{"issue":"18","key":"10.1016\/j.neurot.2025.e00826_bib181","doi-asserted-by":"crossref","first-page":"6149","DOI":"10.1523\/JNEUROSCI.6343-11.2012","article-title":"Targeting the overproduction of peroxynitrite for the prevention and reversal of paclitaxel-induced neuropathic pain","volume":"32","author":"Doyle","year":"2012","journal-title":"J Neurosci"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00826_bib182","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1016\/j.pain.2013.07.032","article-title":"Bioenergetic deficits in peripheral nerve sensory axons during chemotherapy-induced neuropathic pain resulting from peroxynitrite-mediated post-translational nitration of mitochondrial superoxide dismutase","volume":"154","author":"Janes","year":"2013","journal-title":"Pain"},{"issue":"32","key":"10.1016\/j.neurot.2025.e00826_bib183","doi-asserted-by":"crossref","first-page":"10797","DOI":"10.1523\/JNEUROSCI.6345-11.2012","article-title":"Supraspinal peroxynitrite modulates pain signaling by suppressing the endogenous opioid pathway","volume":"32","author":"Little","year":"2012","journal-title":"J Neurosci"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00826_bib184","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1172\/JCI32420","article-title":"Therapeutic manipulation of peroxynitrite attenuates the development of opiate-induced antinociceptive tolerance in mice","volume":"117","author":"Muscoli","year":"2007","journal-title":"J Clin Investig"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00826_bib185","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0304-3959(93)90124-8","article-title":"Nitric oxide (NO) and nociceptive processing in the spinal cord","volume":"52","author":"Meller","year":"1993","journal-title":"Pain"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00826_bib186","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1124\/jpet.103.064154","article-title":"A newly identified role for superoxide in inflammatory pain","volume":"309","author":"Wang","year":"2004","journal-title":"J Pharmacol Exp Therapeut"},{"issue":"11-12","key":"10.1016\/j.neurot.2025.e00826_bib187","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1177\/03331024211017884","article-title":"Targeting reactive nitroxidative species in preclinical models of migraine","volume":"41","author":"Akerman","year":"2021","journal-title":"Cephalalgia"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00826_bib188","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1523\/JNEUROSCI.1366-22.2023","article-title":"Peroxynitrite contributes to behavioral responses, increased trigeminal excitability, and changes in mitochondrial function in a preclinical model of migraine","volume":"43","author":"Lackovic","year":"2023","journal-title":"J Neurosci"},{"key":"10.1016\/j.neurot.2025.e00826_bib189","series-title":"Non-metal PN Scavenger\/Decomposition catalysts for treatment of migraine","author":"Dussor","year":"2018"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00826_bib190","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.pain.2010.12.011","article-title":"Role for peroxynitrite in sphingosine-1-phosphate-induced hyperalgesia in rats","volume":"152","author":"Doyle","year":"2011","journal-title":"Pain"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00826_bib191","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1016\/j.pain.2014.09.016","article-title":"A3 adenosine receptor agonist prevents the development of paclitaxel-induced neuropathic pain by modulating spinal glial-restricted redox-dependent signaling pathways","volume":"155","author":"Janes","year":"2014","journal-title":"Pain"},{"issue":"30","key":"10.1016\/j.neurot.2025.e00826_bib192","doi-asserted-by":"crossref","first-page":"21082","DOI":"10.1074\/jbc.M114.569574","article-title":"The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1","volume":"289","author":"Janes","year":"2014","journal-title":"J Biol Chem"},{"issue":"Pt 1","key":"10.1016\/j.neurot.2025.e00826_bib193","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/brain\/awu330","article-title":"Endogenous adenosine A3 receptor activation selectively alleviates persistent pain states","volume":"138","author":"Little","year":"2015","journal-title":"Brain"},{"issue":"21","key":"10.1016\/j.neurot.2025.e00826_bib194","doi-asserted-by":"crossref","first-page":"10557","DOI":"10.1073\/pnas.1820466116","article-title":"Sphingosine-1-phosphate receptor 1 activation in astrocytes contributes to neuropathic pain","volume":"116","author":"Chen","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00826_bib195","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1084\/jem.20170584","article-title":"Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain","volume":"215","author":"Stockstill","year":"2018","journal-title":"J Exp Med"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00826_bib196","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd3248","article-title":"Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis","volume":"9","author":"Brinkmann","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00826_bib197","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1111\/bph.13476","article-title":"Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity","volume":"173","author":"Scott","year":"2016","journal-title":"Br J Pharmacol"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00826_bib198","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/bph.13446","article-title":"Identification of A3 adenosine receptor agonists as novel non-narcotic analgesics","volume":"173","author":"Janes","year":"2016","journal-title":"Br J Pharmacol"},{"issue":"S1","key":"10.1016\/j.neurot.2025.e00826_bib199","first-page":"138","article-title":"The effect of selective adenosine A3 receptor (A3AR) agonism on migraine-like dural-responsive trigeminocervical neurons","volume":"65","author":"Gamal-Eltrabily","year":"2025","journal-title":"Headache"},{"issue":"S1","key":"10.1016\/j.neurot.2025.e00826_bib200","first-page":"138","article-title":"Targeting the sphingosine-1-phosphate receptor 1 (S1PR1) pathway in preclinical models of migraine-like periorbital hypersensitivity","volume":"65","author":"Rosen","year":"2025","journal-title":"Headache"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00826_bib201","first-page":"30","article-title":"Targeting the S1P-S1PR1 signaling axis in migraine-like dural -responsive trigeminocervical neurons","volume":"44","author":"Salinas-Abarca","year":"2024","journal-title":"Cephalalgia"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00826_bib202","first-page":"81","article-title":"The effect of selective adenosine A3 receptor (A3AR) agonists in preclinical models of migraine-like periorbital hypersensitivity","volume":"44","author":"Torres-Granados","year":"2024","journal-title":"Cephalalgia"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925003046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925003046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T20:25:02Z","timestamp":1780777502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747925003046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":202,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1878747925003046"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00826","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The therapeutic pipeline in migraine: What does the future hold?","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00826","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00826"}}